JP2022031403A5 - - Google Patents

Download PDF

Info

Publication number
JP2022031403A5
JP2022031403A5 JP2021209374A JP2021209374A JP2022031403A5 JP 2022031403 A5 JP2022031403 A5 JP 2022031403A5 JP 2021209374 A JP2021209374 A JP 2021209374A JP 2021209374 A JP2021209374 A JP 2021209374A JP 2022031403 A5 JP2022031403 A5 JP 2022031403A5
Authority
JP
Japan
Prior art keywords
combination according
antigen
antibody
tgfβ1
combination
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021209374A
Other languages
English (en)
Japanese (ja)
Other versions
JP7794630B2 (ja
JP2022031403A (ja
Filing date
Publication date
Priority claimed from PCT/US2017/021972 external-priority patent/WO2017156500A1/en
Application filed filed Critical
Publication of JP2022031403A publication Critical patent/JP2022031403A/ja
Publication of JP2022031403A5 publication Critical patent/JP2022031403A5/ja
Priority to JP2023100034A priority Critical patent/JP2023108057A/ja
Application granted granted Critical
Publication of JP7794630B2 publication Critical patent/JP7794630B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021209374A 2016-03-11 2021-12-23 TGFβ1結合性免疫グロブリンおよびその使用 Active JP7794630B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2023100034A JP2023108057A (ja) 2016-03-11 2023-06-19 TGFβ1結合性免疫グロブリンおよびその使用

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201662307353P 2016-03-11 2016-03-11
US62/307,353 2016-03-11
US201762443615P 2017-01-06 2017-01-06
US62/443,615 2017-01-06
US201762452866P 2017-01-31 2017-01-31
US62/452,866 2017-01-31
PCT/US2017/021972 WO2017156500A1 (en) 2016-03-11 2017-03-10 Tgfb1-binding immunoglobulins and use thereof
JP2018547346A JP2019509737A (ja) 2016-03-11 2017-03-10 TGFβ1結合性免疫グロブリンおよびその使用

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2018547346A Division JP2019509737A (ja) 2016-03-11 2017-03-10 TGFβ1結合性免疫グロブリンおよびその使用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023100034A Division JP2023108057A (ja) 2016-03-11 2023-06-19 TGFβ1結合性免疫グロブリンおよびその使用

Publications (3)

Publication Number Publication Date
JP2022031403A JP2022031403A (ja) 2022-02-18
JP2022031403A5 true JP2022031403A5 (https=) 2022-07-06
JP7794630B2 JP7794630B2 (ja) 2026-01-06

Family

ID=58503696

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018547346A Withdrawn JP2019509737A (ja) 2016-03-11 2017-03-10 TGFβ1結合性免疫グロブリンおよびその使用
JP2021174552A Withdrawn JP2022028680A (ja) 2016-03-11 2021-10-26 TGFβ1結合性免疫グロブリンおよびその使用
JP2021209374A Active JP7794630B2 (ja) 2016-03-11 2021-12-23 TGFβ1結合性免疫グロブリンおよびその使用
JP2023100034A Withdrawn JP2023108057A (ja) 2016-03-11 2023-06-19 TGFβ1結合性免疫グロブリンおよびその使用

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2018547346A Withdrawn JP2019509737A (ja) 2016-03-11 2017-03-10 TGFβ1結合性免疫グロブリンおよびその使用
JP2021174552A Withdrawn JP2022028680A (ja) 2016-03-11 2021-10-26 TGFβ1結合性免疫グロブリンおよびその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023100034A Withdrawn JP2023108057A (ja) 2016-03-11 2023-06-19 TGFβ1結合性免疫グロブリンおよびその使用

Country Status (19)

Country Link
US (2) US11643459B2 (https=)
EP (2) EP3365368B1 (https=)
JP (4) JP2019509737A (https=)
KR (3) KR20180122397A (https=)
CN (1) CN109071646A (https=)
AU (2) AU2017230103A1 (https=)
BR (1) BR112018068340A2 (https=)
CA (1) CA3055555A1 (https=)
DK (1) DK3365368T3 (https=)
EA (1) EA201891909A1 (https=)
ES (1) ES2951648T3 (https=)
FI (1) FI3365368T3 (https=)
HU (1) HUE062976T2 (https=)
IL (2) IL307835A (https=)
MX (2) MX2018010948A (https=)
PL (1) PL3365368T3 (https=)
PT (1) PT3365368T (https=)
SG (1) SG11201807176XA (https=)
WO (1) WO2017156500A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US20190292254A1 (en) * 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
EP3600322A1 (en) * 2017-03-28 2020-02-05 Boehringer Ingelheim International GmbH Nintedanib for use in methods for the treatment of muscular dystrophy
PT3621694T (pt) 2017-05-09 2023-10-09 Scholar Rock Inc Inibidores de lrrc33 e sua utilização
US12358992B2 (en) * 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
US20210115122A1 (en) * 2018-02-23 2021-04-22 Chugai Seiyaku Kabushiki Kaisha Cross-species anti-latent tgf-beta 1 antibodies and methods of use
TW202019957A (zh) 2018-07-11 2020-06-01 美商供石公司 TGFβ1抑制劑及其用途
MX2021000347A (es) 2018-07-11 2021-04-19 Scholar Rock Inc Inhibidores de tgf?1 selectivos de isoforma, de alta afinidad y usos de los mismos.
PL3677278T3 (pl) 2018-07-11 2022-02-28 Scholar Rock, Inc. Selektywne względem izoformy inhibitory tgfbeta1 i ich zastosowanie
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof
WO2020095113A1 (en) * 2018-11-05 2020-05-14 Ludwig Institute For Cancer Research Ltd Humanized and variant tgf-beta1 specific antibodies and methods and uses thereof
AR117918A1 (es) 2019-01-30 2021-09-01 Scholar Rock Inc COMPLEJOS-ESPECÍFICOS LTBP INHIBIDORES DE TGFb Y SUS USOS
CA3135988C (en) * 2019-06-10 2024-11-19 Shandong Boan Biotechnology Co., Ltd. Bifunctional fusion protein against PD-L1 and TGFS and its use
BR112022003412A2 (pt) 2019-08-28 2022-05-24 Chugai Pharmaceutical Co Ltd Anticorpos anti-tgf-beta 1 latente de espécies cruzadas e métodos de uso
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
US20230057012A1 (en) 2020-01-11 2023-02-23 Scholar Rock, Inc. Tgfb inhibitors and use thereof
EP4126919A1 (en) * 2020-03-24 2023-02-08 Bio-Techne Corporation Methods of using a tgf beta knockout cell line and compositions resulting therefrom
CA3208624A1 (en) * 2021-01-18 2022-07-21 Shanghai Jemincare Pharmaceutical Co., Ltd. Garp protein antibody and application thereof
JP7280400B2 (ja) * 2021-02-26 2023-05-23 中外製薬株式会社 種交差性抗潜在型TGF-β1抗体の使用
WO2022180764A1 (en) 2021-02-26 2022-09-01 Chugai Seiyaku Kabushiki Kaisha Uses of cross-species anti-latent tgf-beta 1 antibodies
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
WO2022206753A1 (zh) * 2021-03-29 2022-10-06 山东先声生物制药有限公司 GARP/TGFβ1抗体及其应用
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
EP4370148A1 (en) 2021-07-14 2024-05-22 Scholar Rock, Inc. Ltbp complex-specific inhibitors of tgf beta1 and uses thereof
CA3244596A1 (en) 2022-03-29 2023-10-05 Allogene Therapeutics, Inc. Chimeric switch receivers for converting immunoactive signals into stimulation signals
WO2024023283A1 (en) 2022-07-29 2024-02-01 Institut National de la Santé et de la Recherche Médicale Lrrc33 as a biomarker and biotarget in cutaneous t-cell lymphomas
GB202219154D0 (en) * 2022-12-19 2023-02-01 Metacurum Biotech Ab Antibodies and uses thereof
WO2024149237A1 (zh) * 2023-01-09 2024-07-18 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
PE20252310A1 (es) 2023-02-10 2025-09-22 Chugai Pharmaceutical Co Ltd Anticuerpos anti-tgf-beta 1 latente y metodos de uso
WO2024187051A1 (en) 2023-03-07 2024-09-12 Scholar Rock, Inc. Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients
WO2025240343A1 (en) 2024-05-13 2025-11-20 Scholar Rock, Inc. Tgf-beta inhibitors for treating cancer
CN120131938B (zh) * 2025-03-19 2025-12-23 广州奥奇生物技术有限公司 一种益生菌制剂的制备方法及其在改善睡眠中的应用

Family Cites Families (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
US5262319A (en) 1985-04-19 1993-11-16 Oncogene Science, Inc. Method for obtaining bone marrow free of tumor cells using transforming growth factor β3
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
EP0585287B1 (en) 1990-07-10 1999-10-13 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
EP0575485A1 (en) 1991-03-01 1993-12-29 Dyax Corp. Process for the development of binding mini-proteins
DK0580737T3 (da) 1991-04-10 2004-11-01 Scripps Research Inst Heterodimere receptorbiblioteker ved anvendelse af phagemider
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
GB9601081D0 (en) * 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
CA2250166A1 (en) 1996-03-28 1997-10-02 The Johns Hopkins University Soluble divalent and multivalent heterodimeric analogs of proteins
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US6914128B1 (en) 1999-03-25 2005-07-05 Abbott Gmbh & Co. Kg Human antibodies that bind human IL-12 and methods for producing
US6492497B1 (en) 1999-04-30 2002-12-10 Cambridge Antibody Technology Limited Specific binding members for TGFbeta1
KR100919593B1 (ko) 2000-06-29 2009-09-29 아보트 러보러터리즈 이중 특이성 항체 및 이의 제조 방법 및 이를 포함하는 조성물
GB0230202D0 (en) 2002-12-27 2003-02-05 Domantis Ltd Ligand
JP4653660B2 (ja) 2003-09-04 2011-03-16 独立行政法人理化学研究所 TGF−β活性化制御領域の切断面を認識する抗体
AR045563A1 (es) 2003-09-10 2005-11-02 Warner Lambert Co Anticuerpos dirigidos a m-csf
WO2006086469A2 (en) 2005-02-08 2006-08-17 Genzyme Corporation Antibodies to tgfbeta
ATE505489T1 (de) * 2005-04-22 2011-04-15 Lilly Co Eli Tgf-beta-1-spezifische antikörper
PT2125894T (pt) 2007-03-22 2019-02-27 Biogen Ma Inc Proteínas de ligação incluindo anticorpos, derivados de anticorpos e fragmentos de anticorpos que se ligam especificamente ao cd154 e as suas utilizações
PE20091163A1 (es) 2007-11-01 2009-08-09 Wyeth Corp Anticuerpos para gdf8
US20100260668A1 (en) 2008-04-29 2010-10-14 Abbott Laboratories Dual Variable Domain Immunoglobulins and Uses Thereof
BRPI0913366A8 (pt) 2008-06-03 2017-07-11 Abbott Lab Imunoglobulinas de domínio variável duplo e seus usos
JO3096B1 (ar) 2008-11-07 2017-03-15 Imclone Llc الأجسام المضادة لمستقبل ii مضاد tgfb
WO2011102483A1 (ja) * 2010-02-19 2011-08-25 独立行政法人理化学研究所 ヒトTGF-βのLAPに結合する抗体
UY33421A (es) 2010-06-03 2011-12-30 Glaxo Wellcome House Proteinas de union al antígeno humanizados
JP5918275B2 (ja) 2011-02-08 2016-05-18 アッヴィ・インコーポレイテッド 変形性関節症及び疼痛の治療
SG10201603962TA (en) 2011-05-25 2016-07-28 Innate Pharma Sa Anti-kir antibodies for the treatment of inflammatory disorders
SG195253A1 (en) 2011-06-03 2013-12-30 Xoma Technology Ltd Antibodies specific for tgf-beta
BR112013031485B1 (pt) 2011-06-10 2022-06-14 Medimmune, Llc Anticorpo monoclonal isolado ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, usos e método in vitro para bloqueio ou prevenção da ligação de p. aeruginosa a células epiteliais
CN109111523B (zh) 2011-10-14 2022-06-07 诺华股份有限公司 用于Wnt途径相关疾病的抗体和方法
RU2014114015A (ru) 2011-11-08 2015-12-20 Пфайзер Инк. Способы лечения воспалительных расстройств с использованием антител против m-csf
AU2012339722B2 (en) 2011-11-14 2017-09-14 Regeneron Pharmaceuticals, Inc. Compositions and methods for increasing muscle mass and muscle strength by specifically antagonizing GDF8 and/or Activin A
WO2013134365A1 (en) 2012-03-08 2013-09-12 Ludwig Institute For Cancer Research Ltd TGF-β1 SPECIFIC ANTIBODIES AND METHODS AND USES THEREOF
US20150284455A1 (en) 2012-11-06 2015-10-08 Scholar Rock, Inc. Compositions and methods for modulating cell signaling
EP2968548B1 (en) 2013-03-15 2020-09-09 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the generation and use of conformation-specific antibodies
HRP20251426T1 (hr) 2013-05-06 2026-01-02 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
EP2832747A1 (en) * 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2015015003A1 (en) * 2013-08-01 2015-02-05 Université Catholique de Louvain Anti-garp protein and uses thereof
US20170073406A1 (en) 2014-05-06 2017-03-16 Scholar Rock, Inc. Compositions and methods for growth factor modulation
CN114306596A (zh) 2014-06-26 2022-04-12 海德堡免疫疗法有限公司 抗hsv抗体的局部应用
BR112017009931A2 (pt) 2014-11-18 2018-02-14 Pasteur Institut anticorpos policlonais, agente de diagnóstico, método de detecção de sorogrupo x de neisseria meningitidis in vitro, método in vitro de diagnóstico de infecção no sorogrupo x de neisseria meningitidis, kit e teste de diagnóstico, uso do kit de diagnóstico e método de produção de anticorpos policlonais
EP3244926B8 (en) 2015-01-14 2024-08-21 The Brigham and Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
TWI733661B (zh) 2015-03-04 2021-07-21 美商健臻公司 以高親合性、結合性及特異性結合轉化生長因子-β1的經修飾IgG抗體
WO2017156500A1 (en) 2016-03-11 2017-09-14 Scholar Rock, Inc. Tgfb1-binding immunoglobulins and use thereof
US20190292254A1 (en) 2016-07-14 2019-09-26 Scholar Rock, Inc. TGFBeta Antibodies, Methods and Uses
PE20191661A1 (es) 2017-01-06 2019-11-11 Scholar Rock Inc Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos
EP3694552A1 (en) 2017-10-10 2020-08-19 Tilos Therapeutics, Inc. Anti-lap antibodies and uses thereof
EP3863722A2 (en) 2018-10-10 2021-08-18 Tilos Theapeutics, Inc. Anti-lap antibody variants and uses thereof

Similar Documents

Publication Publication Date Title
JP2022031403A5 (https=)
JP2019509737A5 (https=)
FI3365368T3 (fi) Tgf-beeta-1:tä sitovia immunoglobuliineja ja niiden käyttö
JP2022188083A5 (https=)
JP2017039771A5 (https=)
HRP20210200T1 (hr) Kombinirana antitumorska imunoterapija
CN107148285A (zh) 吡咯并苯并二氮杂*‑抗体缀合物
JP2021534158A5 (https=)
JP2019529476A5 (https=)
JP2015517523A5 (https=)
JP2021105005A5 (https=)
JPWO2020037091A5 (https=)
JPWO2020037092A5 (https=)
JP2022502399A5 (https=)
Vaisitti et al. Vls-101 is a novel therapeutic antibody-drug conjugate (ADC) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1) in Richter's syndrome (RS)
Glaser et al. Complications of intracavitary brachytherapy for gynecologic cancers and their management: a comprehensive review
Freiberger et al. Quality of life up to 10 years after external beam radiotherapy and/or brachytherapy for prostate cancer
Triantafillidou et al. Epithelioid angiosarcoma of the maxillary sinus and the maxilla: a case report and review of the literature
JP2020521786A5 (https=)
JPWO2020051356A5 (https=)
CN110545803A (zh) 用于淋巴结阳性、早期、激素受体阳性、人表皮生长因子受体2阴性乳腺癌的辅助治疗的内分泌疗法和abemaciclib组合
Nasser Applicator for cervical brachytherapy for MRI or CT guided therapy
Verma et al. A rare case of dermoid cyst associated with parotid gland in a male buffalo calf
CN119677533A (zh) 用于治疗癌症的检查点抑制剂与溶瘤病毒的组合
Yu et al. Excellent response with ado-trastuzumab emtansine in a patient with relapsed metastatic breast cancer presenting with pulmonary lymphangitic carcinomatosis